Increasing baricitinib accessibility through prescription discounts - 17/10/25
Doi : 10.1016/j.jaad.2025.07.032
Jack Woll, BSE a, Milan Hirpara, BA a, Colin Kincaid, MD a, Pamela Maree Di Tomasso, PharmD, MS b, Natasha Mesinkovska, MD, PhD a, ⁎ 
a Department of Dermatology, University of California Irvine, Irvine, California
b University of California Irvine Medical Center, Orange, California
∗Correspondence to: Natasha Mesinkovska, MD, PhD, Vice Chair of Clinical Research, Department of Dermatology, University of California Irvine, 843 Health Sciences Rd, Hewitt Hall 1001, Irvine, CA 92697Departmentof DermatologyUniversity of California Irvine843 Health Sciences RdHewitt Hall 1001IrvineCA92697
Key words : alopecia areata, baricitinib, gross sales, JAK inhibitors, payment method, prescription discounts, therapy cost
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
© 2025
The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 93 - N° 5
P. 1330-1332 - novembre 2025 Retour au numéro
Article précédent
- Lower oncogenic risk with dermatologic use of mycophenolate mofetil compared with transplant prophylaxis: A retrospective study
- Robin C. Yi, Ainsley J. Ruley, Aishwarya Sharma, Matthew L. Hrin, Steven R. Feldman, Lindsay C. Strowd
- Effectiveness of tralokinumab for upadacitinib-refractory atopic dermatitis: 48-week retrospective study
- Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?